Hyperandrogenism in Women. Группа авторов

Hyperandrogenism in Women - Группа авторов


Скачать книгу
to adult, prenatally DHT-treated female mice normalizes neuronal connectivity between GABA and GnRH neurons, as well as circulating LH levels, negative feedback regulation of GnRH/LH, ovarian cyclicity and follicle morphology [88], suggesting that extant, extra-ovarian androgen excess is crucial to maintain neuronal reprogramming and its PCOS-like sequelae. Figure 2 illustrates hypothetical sites, implicated by animal models, for specific, androgen receptor-mediated, in utero programming of PCOS-like traits. The implication, emphasized by sheep and transgenic mouse studies, is that abrogation of androgen production and action in specific organ systems may effectively normalize PCOS traits.

Img

      Naturally Occurring in utero Androgen Excess and Female Hyperandrogenism: Origins of PCOS beyond Humans?

Img

      In utero Androgen Excess and Androgen Receptor: Developmental Commonality and Molecular Gateway to PCOS?

      Mounting evidence from human and animal studies repeatedly implicates appropriately timed in utero androgen excess, from either maternal and/or fetal sources, as high risk for PCOS emerging at adolescence. Figure 1 provides a diagrammatic representation of maternal and fetal sources of gestational androgen excess, taken together with relevant PCOS risk genes, may programme for ovarian androgen excess. Figure 2 illustrates hypothetical sites for female reprogramming mediated by androgen receptor, as identified by genetically manipulated mouse studies [17, 18]. Such a unified hypothetical model is compatible with postnatal androgen-activated reprogrammed functions, such that anti-androgens or androgen-diminishing consequences of weight loss interventions, including lifestyle, diet, bariatric surgery, and insulin-sensitizing treatments, ameliorate PCOS traits in adulthood. Increasing sophistication of bioinformatics to assess risk for functional outcome of genomic and epigenomic variants vulnerable to in utero androgen excess, hold promise for identification of PCOS risk in newborn, enabling early intervention.

      Acknowledgment

      We thank Suzanne M. Moenter, PhD, for her comments on an earlier draft of this manuscript.

      Funding Source

      This work was funded, in part, by NIH grants P50 HD028934 (PI: Marshall), P50 HD044405 (PI: Dunaif), and P50 HD071836 (PI: Stouffer).

      Disclosure Statement

      The authors declare that they have no potential conflicts of interest to disclose.

      References


Скачать книгу